AMENDMENT

IN THE CLAIMS:

Please cancel Claim 11.

Please amend Claims 1-5, 12 and 13 as follows.

1. (Amended) A pharmaceutical composition comprising one or more discrete solid orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients, said composition exhibiting upon oral administration a relative bioavailability not less than about 50% by comparison with an orally delivered solution containing celecoxib at the same dosage rate.

2. (Amended) The composition of Claim 1 wherein a single dose unit, upon oral administration to a fasting subject, provides a time course of blood serum concentration of celecoxib having a time to reach maximum concentration (T_{max}) not greater than about 3 h after administration.

3. (Amended) The composition of Claim 1 wherein a single dose unit, upon oral administration to a fasting subject, provides a time course of blood serum concentration of celecoxib having a time to reach maximum concentration (T_{max}) not greater than about 1.7 h after administration.

4. (Amended) The composition of Claim 1 wherein a single dose unit, upon oral administration to a fasting subject, provides a time course of blood serum concentration of celecoxib having a maximum concentration (C_{max}) not less than about 200 ng/ml.

5. (Amended) The composition of Claim 1 wherein a single dose unit, upon oral administration to a fasting subject, provides a time course of blood serum concentration of celecoxib having a maximum concentration (C_{max}) not less than about 400 ng/ml.

12. (Amended) The composition of Claim 1 wherein said discrete solid dose units are selected from the group consisting of tablets, pills, hard and soft capsules, lozenges, sachets and pastilles.

13. (Amended) The composition of Claim 1 in a form of unit dosage capsules or tablets.

Please add the following new claims.

84. (New) The composition of Claim 1 exhibiting upon oral administration a relative bioavailability not less than about 70% by comparison with an orally delivered solution containing celecoxib at the same dosage rate.

85. (New) The composition of Claim 1 having a distribution of celecoxib particle sizes wherein D_{90} of the particles is less than 200 μm, in the longest dimension of said particles.

86. (New) The composition of Claim 1 having a distribution of celecoxib particle sizes wherein D_{90} of the particles is less than 100 μm, in the longest dimension of said particles.

87. (New) The composition of Claim 1 having a distribution of celecoxib particle sizes wherein D_{90} of the particles is less than 40 μm, in the longest dimension of said particles.

88. (New) The composition of Claim 1 having a distribution of celecoxib particle sizes wherein D_{90} of the particles is less than 25 μm, in the longest dimension of said particles.

89. (New) The composition of Claim 1 having a mean celecoxib particle size of about 1 μm to about 10 μm.

90. (New) The composition of Claim 1 having a mean celecoxib particle size of about 5 μm to about 7 μm.

91. (New) The method of Claim 81 wherein the celecoxib is cooled during milling.

92. (New) The method of Claim 90 wherein the cooling is effected using liquid nitrogen.

93. (New) The method of Claim 81 wherein the pin mill is operated with counter rotating disks.

94. (New) The method of Claim 76 wherein the wet granulating step occurs in a high